ETON Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Eton Pharmaceuticals Inc. does not present a strong buy opportunity at this time for a beginner investor with a long-term focus. Despite recent FDA approval for DESMODA, the company's financial performance shows significant net income and EPS declines, and technical indicators are neutral. The lack of strong trading trends, absence of proprietary trading signals, and mixed sentiment suggest holding off on investment until further clarity or improvement in fundamentals emerges.
The MACD is above 0 but positively contracting, indicating weakening momentum. RSI is neutral at 49.242, showing no clear overbought or oversold conditions. Moving averages are converging, and the stock is trading near its support level of 16.298, with resistance at 17.838. Overall, technical indicators are neutral.
FDA approval for DESMODA oral solution for central diabetes insipidus, with projected peak sales of $30-50 million. Product launch scheduled for March 9, 2026, which could drive future revenue growth.
Gross margin dropped by 42.71% YoY, indicating cost pressures. No recent insider or hedge fund activity, and no congress trading data available.
In Q3 2025, revenue increased by 117.54% YoY to $22.46M, but net income dropped to -$1.93M (-407.34% YoY), and EPS fell to -0.07 (-450.00% YoY). Gross margin declined to 34.97%, down 42.71% YoY, reflecting profitability challenges.
No recent analyst rating or price target data available.
